Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Dinesh Talwar

Neurology with Special Qualifications in Child Neurology Tucson, AZ Medical Doctor

NPI 1831168566 CMS profile 128562

2450 E River Rd, Tucson, AZ 85718

Open in the dashboard

General payments

$29,701

202 records reported · program years 2019–2024

Research payments

$4,146

Paid to them · 7 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$495,559 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Dinesh Talwar of Tucson, AZ is reported in the CMS Open Payments database as having received $29,701 across 202 general payments and $4,146 in research payments paid to them. Separately, studies naming them as principal investigator received $495,559 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $2,634 4
2024 Research $2,140 1
2023 General $5,986 22
2022 General $14,164 54
2022 Research $597 2
2021 General $419 21
2021 Research $100 1
2020 General $4,413 29
2020 Research $1,309 3
2019 General $2,085 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dinesh Talwar
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Dinesh Talwar were reported at $0. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Dinesh Talwar Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $2,085 $262 $68–$1,313 $163
2020 $4,413 $188 $46–$1,222 $114
2021 $419 $183 $45–$1,356 $132
2022 $14,164 $229 $72–$1,177 $149
2023 $5,986 $269 $93–$1,195 $160
2024 $2,634 $300 $98–$1,428 $164
2025 $0 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Jazz Pharmaceuticals Inc. $8,569 17 payments
  2. Marinus Pharmaceuticals, Inc. $8,292 12 payments
  3. UCB, Inc. $5,221 25 payments
  4. Sunovion Pharmaceuticals Inc. $3,262 18 payments
  5. Eisai Inc. $1,575 27 payments
  6. Zogenix Inc. $1,016 2 payments
  7. Supernus Pharmaceuticals, Inc. $496 48 payments
  8. SK Life Science, Inc. $325 8 payments
  9. Neurelis, Inc. $163 6 payments
  10. PTC Therapeutics, Inc. $121 1 payment
  11. Other $660 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,628 7 payments
  2. Consulting Fee $9,779 2 payments
  3. Travel and Lodging $4,195 11 payments
  4. Food and Beverage $4,055 180 payments
  5. Honoraria $1,000 1 payment
  6. Education $44 1 payment
Products named General payments · program years 2019–2024
  1. Epidiolex $8,506 20 payments
  2. ZTALMY $8,292 12 payments
  3. Fintepla Neurology $4,912 12 payments
  4. APTIOM $3,268 19 payments
  5. Fycompa $1,575 27 payments
  6. Fintepla Treatment of seizures $1,016 2 payments
  7. OXTELLAR XR $357 37 payments
  8. Briviact $189 12 payments
  9. VALTOCO $163 6 payments
  10. XCOPRI $125 1 payment
  11. Other $765 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Eli Lilly and Company $4,146 7 payments

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$8,583

Medicare's payments for the services billed

Medicare patients

99

Average age 74

Services billed

235

50 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 68%
High blood pressure 65%
Ischemic heart disease 34%
Diabetes 20%
Chronic kidney disease 20%
Depression 19%
COPD 17%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZTALMY
  • Marinus Pharmaceuticals, Inc. $2,601
$2,601 — —
UBRELVY
  • AbbVie, Inc. $17
$17 — —
BOTOX
  • AbbVie, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record